Microtubule/inflammasome (tubulin)

Class

Anti-inflammatory (low-dose, CV-specific)

This mechanism centers on tubulin, the structural protein that polymerizes into microtubules, the filament network that gives cells shape and transports internal cargo. Certain small molecules bind tubulin and prevent microtubule assembly. Because microtubules are required for the movement and activation of white blood cells, and for assembly of the NLRP3 inflammasome (a multiprotein complex that triggers release of inflammatory signaling proteins such as interleukin-1 beta), disrupting microtubule dynamics dampens innate immune activation. In cardiovascular disease, this matters because atherosclerotic plaques are not purely fatty deposits but sites of ongoing low-grade inflammation driven by immune cells; that inflammation contributes to plaque instability and rupture, which can trigger heart attacks and strokes. At low, carefully calibrated doses, a microtubule-targeting agent can suppress this inflammatory component without producing the broader antimitotic effects seen at higher doses used in other settings, such as gout flares. The rationale for using this mechanism in cardiovascular disease is thus to address a residual inflammatory driver of vascular events that lipid-lowering therapies alone do not fully resolve, rather than to treat cholesterol or clotting directly.